PHASE I STUDY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS

腹膜癌患者的 I 期研究

• 批准号: 6279650
• 负责人: DENNIS J SLAMON
• 金额: $ 1.77万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6279650
• 关键词: antibody; carcinoma; clinical research; clinical trial phase I; gene mutation; human subject; human therapy evaluation; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; ovary neoplasms; peritoneum neoplasm; tumor suppressor genes

Up to 80% of ovarian cancer patients have tumors demonstrating p53 mutation. Antibodies to p53 are found in high numbers in patients with ovarian tumors. There was a high correlation of this finding with the presence of mutation for the p53 gene. In addition, the specificity was high (approaching 100% for ovarian cancer) but the sensitivity was quite low (approximately 15% for ovarian cancer). The incidence of p53 mutation has been correlated with the degree of malignant potential and was more commonly found in ovarian carcinoma.

多达80％的卵巢癌患者患有肿瘤证明p53 突变。 在患有p53抗体的抗体中，有大量的患者 卵巢肿瘤。 这个发现与 p53基因的突变存在。 另外，特异性是 高（卵巢癌的100％接近100％），但敏感性很大 低（大约15％的卵巢癌）。 p53的发病率 突变与恶性潜力程度相关， 在卵巢癌中更常见。